European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00217763
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Brief Summary
The purpose of this Phase 3 study is to evaluate the efficacy and safety of 3APS as an add-on therapy to most standard medication for Alzheimer's disease compared to placebo (inactive substance pill) in patients with mild to moderate Alzheimer's disease.
- Detailed Description
* Duration of treatment: 18 months
* 3 treatment arms:
Placebo and 2 different doses of active drug.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 930
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (48)
Middelheim Ziekenhuis Lindendreef
🇧🇪Antwerp, Belgium
University Hospital Antwerp - Neurology - Prof. Dr. Patrick Cras, MD, PhD
🇧🇪Edegem, Belgium
Memory Clinic University Hospital Gasthuisberg, Neurology Department
🇧🇪Leuven, Belgium
Memory Centre, Polycliniques Brull, CHU de Liège
🇧🇪Liege, Belgium
Hôpital Pellegrin CHU de Bordeaux
🇫🇷Bordeaux, France
Centre Hospitalier Régional Universitaire de Lille
🇫🇷Lille, France
Hôpital Sainte Marguerite Service de neuro-geriatrie
🇫🇷Marseille, France
Hôpital Gui de Chauliac - Service de Neurologie du Pr J. Touchon
🇫🇷Montpellier, France
Centre Mémoire de Ressources et de Recherche Hôpital Pasteur
🇫🇷Nice, France
Hôpital BROCA
🇫🇷Paris, France
Scroll for more (38 remaining)Middelheim Ziekenhuis Lindendreef🇧🇪Antwerp, Belgium